Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HepBVac-J2: Phase I/II trial of NASVAC (HBsAg + HBcAg) nasal vaccine
jRCTs061180101Phase 2Completed
- Start
- Jan 2017
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of ABX203 in hepatitis B (HBV) (3 arms). Primary endpoint: Anti-HBs induction. Started Jan 2017; status: completed.
02
Drugs
ABX203
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on jRCTs061180101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061180101.